sorafenib has been researched along with amygdalin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (amygdalin) | Trials (amygdalin) | Recent Studies (post-2010) (amygdalin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 663 | 22 | 193 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attia, AA; El-Magd, MA; El-Naggar, SA; Eldiasty, JG; Elmetwalli, A; Mosallam, SAE; Nasser, HM; Salama, AF | 1 |
1 other study(ies) available for sorafenib and amygdalin
| Article | Year |
|---|---|
Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.
Topics: Amygdalin; Animals; Antioxidants; Ascites; Carcinoma, Ehrlich Tumor; Liver; Matrix Metalloproteinase 9; Mice; Neoplasms; NF-E2-Related Factor 2; Sorafenib; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2022 |